Abstract
Introduction
Non-alcoholic fatty liver disease (NAFLD) has become a major cause of chronic liver disease world wide and 25% of the global adult population is potentially affected by the disease. A total of 3% to 10% of all children and about 34% of children who are obese in developed countries are thought to have NAFLD. The increasing prevalence of these diseases is related to unhealthy lifestyles, particularly unhealthy diet, which increases NAFLD. NAFLD are often found those who are obese or have features of poor metabolic health even at normal weight. NAFLD is relatively under diagnosed and long-term outcomes of hepatic and extrahepatic manifestations of NAFLD are compromised. Liver plays a crucial role in lipid and glucose homeostasis and stays in the center of cardiometabolic disease. Thus imbalance in calorie-intake and expenditure leads into deposition of fat in the liver. NAFLD is part of and victim of metabolic derangement and in the emergence of cardiovascular disease, type 2 diabetes, and chronic kidney disease. Compared with healthy individuals, persons with NAFLD had a 1.5 -6 times higher risk of cardiovascular disease, diabetes. NAFLD can be categorised histologically into non-alcoholic fatty liver and non-alcoholic steatohepatitis (NASH). Non-alcoholic fatty liver is defined as the presence of atleast 5% hepatic steatosis without evidence of hepatocellular injury. NASH is defined as the presence of a least 5% hepatic steatosis and inflammation with hepatocyte injury with or without fibrosis. Cardiovascular disease is the main cause of death in NAFLD patients. Patients with NAFLD exhibit endothelial dysfunction of conducting vessels, stiffness of arterioles and carotid intimal media thickness. Endothelial dysfunction of the systemic circulation is mainly due to asymmetric dimethylarginine (ADMA) is an endogenous antagonist of nitric oxide synthase, positively linked with CVD. Other markers for endothelial dysfunction is endocan. Beside that the level of circulating endothelial progenitor cells is also reduced in NAFLD, which has endothelial repair activity. The liver is the main organ handling amino acids including homocysteine. Elevated serum homocysteine is frequently reported in NAFLD. Homocysteine causes disruption of the intrahepatic vasculature with impaired nitric oxide formation. Hepatic microvasculature shows distortion of the sinusoidal pattern, which leads into increase in portal pressure. Vascular endothelial growth factor (VEGF), plasminogen inhibitor activator 1 level is increased in NAFLD patients, which has an active role in atherogenesis and plaque formation. Factor VII, von willebrand factor level is also increased and antithrombin III is decreased. NAFLD patients are in thrombotic state resulting in increase in blood viscosity with increased cardiovascular disease. Increased circulating markers IL-6, TNF alpha,CCL3, sICAM-1,hsCRP in NAFLD related to cardiovascular disease. Fetuin-A (FetA) is a hepatokine has positive link between NAFLD and cardiovascular disease. Adipokines are implicated in NAFLD and CVD.
Materials and Method
It was a cross sectional study done on 40 patients admitted in medicine department of AGMC & GBP Hospital, Agartala between April.2018 to Nov.2018.
Inclusion Criteria
• Adult patients with cirrhosis of liver and no significant alcohol consumption (defined as greater than 40 grams per day).
Exclusion Criteria
• Patients with HBV, HCV positivity.
• Liver diseases of other known causes.
• Patients consuming significant amount of alcohol or druds such as ATT, estrogen, methotrexate, tamoxifen, amiodarone.
• Pregnant women.
• Unwiling or incapacity to provide informed consent.
Method of Data Collection
Patients who has undergone USG of whole abdomen examination in the Radiology department for some or other reason with no history of alcohol intake. Cardiovascular function was evaluated with ECG and echocardiography.
Operational definitions Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD is defined as the presence of fat in the liver either on imaging or on liver histology after the exclusion of secondary causes of fat accumulation in the liver.
Non-Alcoholic Steato Hepatitis (NASH)
When NAFLD is associated with raised transaminase levels, the diagnosis of NASH is made (Normal AST 12-38 U/L and ALT 7-41U/L
Statistical analysis
The collected data has been summarized in terms of tables and figures. The arithmetic mean and standard deviation has been calculated. Chi square test has been used to find association between two categorical variables. A p value of <0.05 has been considered statistically significant. Data analysis was done using SPSS version 20.
A total of 40 patients were worked up according to the procedure detailed in the methodology and the data obtained thereby was presented and analysed. 
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